CELU CELULARITY INC Other Situations 8-K Filing 2023 - Preliminary Trial Results Celularity Inc. announced preliminary results from its Phase 1 trial of CYNK-001 for the treatment of relapsed refractory acute myeloid leukemia (AML) and measurable residual disease-positive AML.Get access to all SEC 8-K filings of the CELULARITY INC